Drugs / GSK-923295A
GSK-923295A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00504790 | Jun 2007 → May 2012 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK-923295A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303470 ↗ |
| Known as | GSK-295 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303470 ↗ |
| Known as | GSK923295 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00504790 ↗ |
| Action | Inhibit | “GSK923295 is a potent and selective CENP-E inhibitor” NCT00504790 ↗ |
| Modality | Small molecule | — CHEMBL4303470 ↗ |
| Route | Intravenous | “GSK923295 will be administered intravenously over one hour” NCT00504790 ↗ |